TheraRadar
← Back
Data updated: Jun 28, 2026

LANTHEUS

Pharma
CardiovascularNeurologyOncology Execution: Good

LANTHEUS is a pharmaceutical company focused on Cardiovascular, Neurology, Oncology. Key products include NEURACEQ.

2014
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

LANTHEUS at a Glance

  • Fast trial execution (10 months median completion)

Upcoming FDA Decisions

Full Calendar →
Aug 13, 2026 — LNTH

LANTHEUS's Key Drugs

LANTHEUS's core commercial portfolio centers on NEURACEQ, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.

NEURACEQ
CNS

Alzheimer's Disease

Approved 2014

LANTHEUS's Recent FDA Approvals

New NDA/BLA approvals for LANTHEUS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

LANTHEUS's Therapeutic Areas

LANTHEUS's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 50%
0 drugs Phase 3: 3 Phase 2: 1 Phase 1: 3
Neurology 29%
1 drugs Phase 3: 1
Oncology 15%
0 drugs Phase 2: 1 Phase 1: 3
Gastroenterology 3%
0 drugs Phase 1: 1
Respiratory 3%
0 drugs Phase 1: 1

LANTHEUS's Top Competitors

LANTHEUS's closest competitors by therapeutic-area and drug-target overlap include Novartis, GE HEALTHCARE, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Novartis big-pharma
Oncology, Cardiovascular, Respiratory
GE HEALTHCARE specialty
Neurology, Cardiovascular, Oncology, Respiratory
Merck big-pharma
Oncology, Cardiovascular, Respiratory
AZURITY specialty
Cardiovascular, Oncology, Neurology, Respiratory
Bayer big-pharma
Oncology, Cardiovascular, Respiratory

LANTHEUS Pipeline Snapshot

LANTHEUS has 14 active clinical programs from ClinicalTrials.gov — 4 Phase 3, 2 Phase 2 and 8 Phase 1.

4
Phase 3
2
Phase 2
8
Phase 1

Phase 3 Readout Calendar Pro

1 Phase 3 trial with confidence-graded primary completion dates.

Full calendar →
Q2 2027
[18F]PI-2620
Alzheimer Disease
Estimated · fresh NCT05641688

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • NEURACEQ leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Cardiovascular pipeline focus
  • • 1 Phase 3 readout tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 3/4 completed
  • • Speed: 10 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges